Detalhe da pesquisa
1.
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
Lancet Oncol
; 15(11): 1195-206, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-25242045
2.
Regional differences in treatment and outcome for myeloma patients in Sweden: A population based Swedish myeloma register study.
Cancer Rep (Hoboken)
; 5(11): e1614, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35243814
3.
Melphalan 100 mg/m2 with stem cell support as first relapse treatment is safe and effective for myeloma patients with long remission after autologous stem cell transplantation.
Eur J Haematol
; 87(2): 117-22, 2011 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-21535157
4.
Serum metabolomic profiling correlated with ISS and clinical outcome for multiple myeloma patients treated with high-dose melphalan and autologous stem cell transplantation.
Exp Hematol
; 97: 79-88.e8, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33609593
5.
Sequence variation at the MTHFD1L-AKAP12 and FOPNL loci does not influence multiple myeloma survival in Sweden.
Blood Cancer J
; 9(8): 57, 2019 07 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-31363079